SML0613
Rofecoxib
≥98% (HPLC)
Synonym(s):
4-[4-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C17H14O4S
CAS Number:
Molecular Weight:
314.36
UNSPSC Code:
12352200
NACRES:
NA.77
Product Name
Rofecoxib, ≥98% (HPLC)
SMILES string
[S](=O)(=O)(C)c1ccc(cc1)C2=C(C(=O)OC2)c3ccccc3
InChI
1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3
InChI key
RZJQGNCSTQAWON-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL, clear (warmed)
storage temp.
2-8°C
Quality Level
Related Categories
Application
Rofecoxib has been used in high performance bioaffinity chromatography.
Biochem/physiol Actions
Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with >800-fold COX-2 selectivity in CHO cells expressing human COX-1 and COX-2.
Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor.
Rofecoxib is derived from furanone and has the ability to cross human placenta. Along with anti-inflammatory action, it possesses analgesic and antipyretic properties. Cytosolic hepatic enzymes are responsible for the metabolism of rofecoxib. It is known to cause oligohydramnios and ductus arteriosus constrictions. Rofecoxib inhibits the action of CYP1A2 (cytochrome P450 family 1 subfamily A member 2). It might be associated with aseptic meningitis. Rofecoxib is known to ameliorate the risk of colorectal adenoma, but might contribute to toxicity.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
J Patrick O'Connor et al.
Acta orthopaedica, 80(5), 597-605 (2009-11-18)
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) activity, which is the rate-limiting enzyme in the synthesis of prostaglandins. Previous studies have indicated that NSAID therapy, and in particular NSAIDs that specifically target the inflammatory cyclooxygenase (COX-2), impair bone healing. We
Krista F Huybrechts et al.
Medical care, 55(6), 545-551 (2017-05-16)
Many countries lack fully functional pharmacovigilance programs, and public budgets allocated to pharmacovigilance in industrialized countries remain low due to resource constraints and competing priorities. Using 3 case examples, we sought to estimate the public health and economic benefits resulting
Handbook of Drug Interactions: A Clinical and Forensic Guide, 361-361 (2003)
Drugs for Pregnant and Lactating Women, 1011-1011 (2009)
Kerstin Rabausch et al.
Circulation research, 96(1), e1-e6 (2004-12-14)
There is concern that cyclooxygenase (COX)-2 inhibitors may promote atherothrombosis by inhibiting vascular formation of prostacyclin (PGI2) and an increased thrombotic risk of COX-2 inhibitors has been reported. It is widely accepted that the prothrombotic effects of COX-2 inhibitors can
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service